Quincy, MA, United States of America

James M Duerr

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Pfizer Corporation. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James M Duerr. Retrieved from https://idiyas.com/inventor/james-m-duerr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: James M Duerr: Innovator in Pharmaceutical Chemistry

Introduction

James M Duerr is a notable inventor based in Quincy, Massachusetts. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds.

Latest Patents

James M Duerr holds a patent for pyrrolo[2,3-d]pyrimidine derivatives. This patent describes the use of these derivatives as Janus Kinase (JAK) inhibitors, along with pharmaceutical compositions containing them and their therapeutic applications.

Career Highlights

Duerr is currently employed at Pfizer Corporation, a leading global pharmaceutical company. His work focuses on the development of new therapeutic agents that can address various medical conditions.

Collaborations

Throughout his career, James has collaborated with esteemed colleagues, including Michael L Vazquez and Neelu Kaila. These partnerships have contributed to the advancement of research and innovation in the pharmaceutical sector.

Conclusion

James M Duerr exemplifies the spirit of innovation in the pharmaceutical industry through his groundbreaking work and collaborations. His contributions continue to impact the field positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…